AVAXZIPEN
LIVE

Serial Number

79388905

Owner

AVAXZIPEN LIMITED

Attorney

Rebecca Liebowitz

Filing Date

Mar 31, 2023

Add to watchlist:

No watchlists yet
View on USPTO

AVAXZIPEN Trademark

Serial Number: 79388905 • Registration: 7656600

AVAXZIPEN is a trademark filed by AVAXZIPEN LIMITED on March 31, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

AVAXZIPEN LIMITED

120A & B Olympic Avenue,

Entity Type: 99

AVAXMED LIMITED

120A & B Olympic Avenue,

Entity Type: 98

Trademark Details

Filing Date

March 31, 2023

Registration Date

January 21, 2025

Published for Opposition

December 3, 2024

Goods & Services

Pharmaceutical, biopharmaceutical and veterinary preparations and substances for the treatment of and protection against disease; pharmaceutical, biopharmaceutical and veterinary preparations and substances for the treatment of or protection against viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders; prophylactic pharmaceutical and veterinary preparations and substances, namely for the treatment of infectious and autoimmune diseases; vaccines; prophylactic vaccines; therapeutic vaccines; vaccine preparations; biological preparations for medical use, namely, mixed biological preparations for the prevention and treatment of infectious and autoimmune diseases; biological, chemical and biochemical reagents for medical use; contraceptive preparations and substances, namely, oral, chemical and parenteral based contraceptives

Medical and veterinary research and product development services; medical and veterinary device development services; pharmaceutical and biopharmaceutical development services; Product development of pharmaceutical and biopharmaceutical delivery systems; Pharmaceutical and biopharmaceutical product development, namely research and formulation of pharmaceuticals and biopharmaceuticals; research into vaccines; Product testing services for medical and veterinary devices and products; provision of information relating to product development and testing; Consulting services in the field of product development and testing

Surgical apparatus and instruments; medical, dental and veterinary apparatus and instruments, namely, injection and infusion devices for administering pharmaceutical, biopharmaceutical and veterinary preparations; drug delivery devices sold empty, namely, injection devices; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations parenterally; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into subcutaneous tissue; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intradermal tissue; actuator devices being injection devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intramuscular tissue; drug delivery devices, namely, drug cassettes sold empty; drug delivery devices, namely medical injectors, needle-free injectors, injectors with needles, all sold empty; drug delivery devices, sold empty, namely, medical injectors, needle-free injectors and parts and fittings therefore; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices for injecting pharmaceutical, biopharmaceutical and veterinary preparations parenterally; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into subcutaneous tissue; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intradermal tissue; actuator devices for use in drug delivery devices, namely handheld spring-powered and handheld gas-powered devices sold empty for injecting pharmaceutical, biopharmaceutical and veterinary preparations into intramuscular tissue; pre-loaded drug cassettes for use in drug delivery devices to contain pharmaceutical and biopharmaceutical preparations and substances for therapeutic, prophylactic and diagnostic use; Structural parts and fittings for all the aforesaid goods

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 5, 2026 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 23, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 5, 2025 FICS
FINAL DISPOSITION PROCESSED
Aug 5, 2025 FIMP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 26, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 7, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 7, 2025 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 22, 2025 FICR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 8, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 8, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 8, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 8, 2025 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 21, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 21, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 4, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 25, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 24, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 24, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 16, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 25, 2024 RFCS
REFUSAL PROCESSED BY MPU
Mar 25, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 2, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 1, 2024 CNRT
APPLICATION FILING RECEIPT MAILED
Feb 16, 2024 MAFR
ASSIGNED TO EXAMINER
Feb 12, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 9, 2024 REPR